durlobactam   Click here for help

GtoPdb Ligand ID: 12693

Synonyms: ETX-2514 | EXT2514 | Xacduro® (sulbactam and durlobactam)
Approved drug
durlobactam is an approved drug (FDA (2023))
Compound class: Synthetic organic
Comment: Durlobactam (ETX2514) is a broad-spectrum diazabicyclooctanone (DBO) class non-beta-lactam beta-lactamase inhibitor [1]. It reduces beta-lactamase-mediated degradation of beta-lactam antibacterials, and has been demonstrated to restore sulbactam activity against Acinetobacter species, including contemporary multidrug-resistant strains [4]. There is evidence that a few carbapenem- and colistin-resistant, metallo beta-lactamase (MBL)-producing strains of A. baumannii are resistant to sulbactam/durlobactam dual therapy [2,5].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 3
Topological polar surface area 138.62
Molecular weight 277.26
XLogP -3.64
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1=C[C@@H]2CN([C@@H]1C(=O)N)C(=O)N2OS(=O)(=O)O
Isomeric SMILES CC1=C[C@@H]2CN([C@@H]1C(=O)N)C(=O)N2OS(=O)(=O)O
InChI InChI=1S/C8H11N3O6S/c1-4-2-5-3-10(6(4)7(9)12)8(13)11(5)17-18(14,15)16/h2,5-6H,3H2,1H3,(H2,9,12)(H,14,15,16)/t5-,6+/m1/s1
InChI Key BISPBXFUKNXOQY-RITPCOANSA-N
No information available.
Summary of Clinical Use Click here for help
Durlobactam was approved by the FDA in May 2023. It is approved for intravenous (IV) infusion in combination with sulbactam to treat hospital-acquired and ventilator-associated bacterial pneumonias that are caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03894046 Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex Phase 3 Interventional Entasis Therapeutics 3
NCT03445195 Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections Phase 2 Interventional Entasis Therapeutics